Pancreatic Cancer Research

ResearcherUniversity of CopenhagenActive in the last 2 years

Rosalie C. Sears

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1558-2413; OpenAlex author ID A5081536984; NIH RePORTER profile ID 1938469. Sources: OpenAlex.

Their work

Papers
55 (first author 2, last author 10)
Trials
0
Grants
5
Labs led
1
Collaborators
223
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper, 1 grant · 2020: 4 papers · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers, 2 grants · 2024: 7 papers · 2025: 15 papers, 1 grant · 2026: 13 papers, 1 grant

Papers 50 of 55

  1. Liquid Biopsy Differentiation of Pancreatic Cancer From Non-Cancerous Pancreatic Disease Using Dielectrophoresis-Recovered Nanoparticles Carrying Cell-Free DNA… Co-author DOI 10.1002/smll.202502532↗
  2. Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design. Co-author DOI 10.1016/j.canlet.2026.218864↗
  3. Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression. Co-author DOI 10.1038/s41588-026-02779-5↗
  4. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.08.034↗
  5. IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-25-1612↗
  6. The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1136/jitc-2025-sitc2025.1250↗
  7. Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Co-author DOI 10.1158/2767-9764.crc-25-0338↗
  8. Sympathetic nerve-fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic cancer. Co-author DOI 10.1172/jci.insight.192814↗
  9. Surveillance for Pancreatic Cancer: Knowledge, Motivations, Barriers, and Preferences Among High-Risk Individuals and Underserved Populations. Co-author DOI 10.1177/10732748261468819↗
  10. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  11. The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective S… Co-author DOI 10.3390/jcm15197355↗
  12. Spatially Resolved Epithelial States Delineate Immunosuppressive Niches of Impaired Myeloid Antigen Presentation in PDAC Co-author DOI 10.64898/2026.07.28.741300↗
  13. Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells Last author DOI 10.64898/2026.09.28.754674↗
  14. Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer. Co-author DOI 10.1016/j.devcel.2024.12.003↗
  15. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2025.101152↗
  16. Protocol to purify and culture human pancreatic cancer cells from patient-derived xenografts. Co-author DOI 10.1016/j.xpro.2025.103672↗
  17. Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients. Co-author DOI 10.1038/s41467-025-62685-y↗
  18. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Last author DOI 10.1038/s43018-024-00881-3↗
  19. Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer. Co-author DOI 10.1038/s43018-025-01003-3↗
  20. Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.02.07.632847↗
  21. Long Noncoding RNAs Preserve Pancreatic Cancer Identity and Resist Cell Fate Conversion Co-author DOI 10.1101/2025.06.25.661419↗
  22. Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model Last author DOI 10.1101/2025.07.14.664767↗
  23. Early detection of pancreatic cancer by a high-throughput protease-activated nanosensor assay. Co-author DOI 10.1126/scitranslmed.adq3110↗
  24. The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3437↗
  25. Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate. Co-author DOI 10.1158/1078-0432.ccr-25-2333↗
  26. HuR-Regulated Extracellular Vesicles Promote Endothelial Cell Remodeling in Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-25-0355↗
  27. MicroCT Enables Simultaneous Longitudinal Tracking of Murine Pancreatic Cancer Progression and Cachexia. Co-author DOI 10.1158/2767-9764.crc-25-0414↗
  28. A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Last author DOI 10.64898/2025.12.12.693851↗
  29. Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells. Co-author DOI 10.1016/j.heliyon.2024.e27221↗
  30. KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development. Co-author DOI 10.1038/s41388-024-03196-w↗
  31. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Last author DOI 10.1080/14796694.2024.2395235↗
  32. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Co-author DOI 10.1080/15384047.2024.2421584↗
  33. A high throughput blood-based assay for the early detection of pancreatic cancer Co-author DOI 10.1101/2024.01.12.24301220↗
  34. Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency. Co-author DOI 10.3791/65811↗
  35. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  36. Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma. First author DOI 10.1038/s43856-023-00351-4↗
  37. Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. Co-author DOI 10.1093/narcan/zcad016↗
  38. Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment. Last author DOI 10.3390/pharmaceutics15122651↗
  39. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  40. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00018-22↗
  41. Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. Co-author DOI 10.1158/0008-5472.can-21-4222↗
  42. HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Co-author DOI 10.3390/cancers14071848↗
  43. Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics14040713↗
  44. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  45. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  46. Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma. Last author DOI 10.1200/po.20.00287↗
  47. Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. Co-author DOI 10.1016/j.canlet.2020.07.041↗
  48. Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer. Co-author DOI 10.1084/jem.20191805↗
  49. Regulation of HDAC2-PDX1 by RNF125 defines pancreatic cancer development Co-author DOI 10.1101/2020.01.06.896555↗
  50. Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC. First author DOI 10.1158/2159-8290.cd-20-0046↗

Grants 5

  1. Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs U01CA278923↗
  2. An atlas of pancreatic tumorigenesis in the context of altered DNA repair occurring in high-risk individuals U01CA294548↗
  3. Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancers R21CA263996↗
  4. Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens U01CA224012↗
  5. The Role of post-translational activation of Myc in pancreatic cancer R01CA196228↗

Closest collaborators

The 25 strongest of 223 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonathan Robert Brody · 16 shared papers, 3 shared grants, 2022–2026 · strength 5.08
  2. Brett C. Sheppard · 20 shared papers, 1 shared grant, 2014–2026 · strength 4.10
  3. Lisa M. Coussens · 9 shared papers, 1 shared grant, 2021–2026 · strength 2.10
  4. Kevin Hawthorne · 9 shared papers, 2025–2026 · strength 1.93
  5. Charles D. Lopez · 11 shared papers, 2014–2026 · strength 1.82
  6. Terry K. Morgan · 10 shared papers, 2021–2026 · strength 1.80
  7. Jason M. Link · 11 shared papers, 2017–2026 · strength 1.71
  8. Alexander Savio Ramos Guimaraes · 4 shared papers, 1 shared grant, 2023–2026 · strength 1.64
  9. Brittany L. Allen-Petersen · 10 shared papers, 2014–2025 · strength 1.44
  10. Motoyuki Tsuda · 8 shared papers, 2023–2026 · strength 1.40
  11. Jennifer M. Finan · 6 shared papers, 2023–2026 · strength 1.26
  12. Katie E. Blise · 6 shared papers, 2025–2026 · strength 1.21
  13. Gregory A. Coté · 1 shared paper, 1 shared grant, 2026 · strength 1.16
  14. Vidhi M. Shah · 7 shared papers, 2020–2026 · strength 1.15
  15. Aaron J. Grossberg · 6 shared papers, 2021–2026 · strength 1.12
  16. Gordon Brent Mills · 6 shared papers, 2024–2026 · strength 1.09
  17. Isabel A. English · 6 shared papers, 2020–2025 · strength 1.06
  18. Patrick Joseph Worth · 6 shared papers, 2017–2026 · strength 1.04
  19. Grace A. McCarthy · 5 shared papers, 2022–2026 · strength 0.91
  20. Laura DeLong Wood · 1 shared paper, 1 shared grant, 2025 · strength 0.90
  21. Ellen M. Langer · 5 shared papers, 2023–2026 · strength 0.89
  22. Katherine R. Pelz · 5 shared papers, 2019–2026 · strength 0.89
  23. Zheng Xia · 4 shared papers, 2025–2026 · strength 0.87
  24. Canping Chen · 4 shared papers, 2025–2026 · strength 0.87
  25. Dmytro Grygoryev · 4 shared papers, 2024–2025 · strength 0.84

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.